RT @DrJohnB2: (3/n) - As early as June 2020, it was hypothesised that NCCs could be key in explaining severe COVID-19 courses: https://t.co…
RT @DrJohnB2: (3/n) - As early as June 2020, it was hypothesised that NCCs could be key in explaining severe COVID-19 courses: https://t.co…
RT @DrJohnB2: (3/n) - As early as June 2020, it was hypothesised that NCCs could be key in explaining severe COVID-19 courses: https://t.co…
RT @DrJohnB2: (3/n) - As early as June 2020, it was hypothesised that NCCs could be key in explaining severe COVID-19 courses: https://t.co…
RT @DrJohnB2: (3/n) - As early as June 2020, it was hypothesised that NCCs could be key in explaining severe COVID-19 courses: https://t.co…
RT @DrJohnB2: (3/n) - As early as June 2020, it was hypothesised that NCCs could be key in explaining severe COVID-19 courses: https://t.co…
RT @DrJohnB2: (3/n) - As early as June 2020, it was hypothesised that NCCs could be key in explaining severe COVID-19 courses: https://t.co…
RT @DrJohnB2: (3/n) - As early as June 2020, it was hypothesised that NCCs could be key in explaining severe COVID-19 courses: https://t.co…
RT @DrJohnB2: (3/n) - As early as June 2020, it was hypothesised that NCCs could be key in explaining severe COVID-19 courses: https://t.co…
RT @DrJohnB2: (3/n) - As early as June 2020, it was hypothesised that NCCs could be key in explaining severe COVID-19 courses: https://t.co…
RT @DrJohnB2: (3/n) - As early as June 2020, it was hypothesised that NCCs could be key in explaining severe COVID-19 courses: https://t.co…
(3/n) - As early as June 2020, it was hypothesised that NCCs could be key in explaining severe COVID-19 courses: https://t.co/yJPXeXcku0 https://t.co/nC4xbZzwI5
@Milesdominic @CastricumJoris @huisdoktertim @MarionKoopmans @BleekerRovers "Reduced circulating NK cell levels and exhaustion may be directly responsible for progression and severity of COVID-19." https://t.co/xluvHyiNGw
Flattening the COVID-19 Curve With NK Cell Based Immunotherapies https://t.co/SrYjbqnTFT To gain mechanistic & therapeutic insights into COVID-19: https://t.co/6ySOYVgCcD https://t.co/ZGNRi4CquW @DrLBoominathan https://t.co/8Bx495Uig3
The NK cells being discussed in the email are Natural Killer lymphocytes. Tony is sure China is working on NK cells, but he doesn't know if the US is. The email is March 1, 2020, the first cited NIH study I found was June 23, 2020. https://t.co/jl3KsOMYaN
Covid-19 VS NK cells /อยากรู้แต่ขี้เกียจอ่าน 😅😅😅 https://t.co/TgRCLS6WSd
“pts recovering from #COVID-19 had higher nrs of #NK cells... ” 👉 cld explain “resembling”, then “seperating” #ME from covid . #MEICC : #NKD hallmark feature. No “NK recovering”. vs #postcovid : #NK restores #MedTwitter @PaulGardnerNZ https://t.
RT @CdnImmunol: Natural killer (NK) cells are key to clearing viral infections, especially in the initial phases. Asymptomatic or mildly sy…
RT @CdnImmunol: Natural killer (NK) cells are key to clearing viral infections, especially in the initial phases. Asymptomatic or mildly sy…
Natural killer (NK) cells are key to clearing viral infections, especially in the initial phases. Asymptomatic or mildly symptomatic #COVID19 patients are rarely diagnosed which makes them challenging to study. @auer_r @QFKC - SN https://t.co/JcUDSDIBS9
Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies. https://t.co/PVQkIwUpRk
@kevinclosson How was it beaten? Chemo is nasty. Proton has economic problems. The trend is toward specific characteristics of tumors, as well as training killer cells, extremely expensive. But what is yet to be done is untraining autoimmune problems. htt
Stimulating NK cells to take out SARS CoV-2. https://t.co/397m8E4xl3
Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies. by Market M, Angka L, Martel AB, Bastin D, Olanubi O, Tennakoon G, Boucher DM, Ng J, Ardolino M, Auer RC https://t.co/qE1zVMfj22
RT @amartelmd: Proud of my lab for publishing this excellent COVID-19 review paper focusing on NK cell therapies @auer_r @mikennedyPhD http…
RT @amartelmd: Proud of my lab for publishing this excellent COVID-19 review paper focusing on NK cell therapies @auer_r @mikennedyPhD http…
RT @amartelmd: Proud of my lab for publishing this excellent COVID-19 review paper focusing on NK cell therapies @auer_r @mikennedyPhD http…
RT @LeonardAngka: Double feature of #naturalkiller cells and #COVID19 both officially out today! @jclinicalinvest https://t.co/ZNFRQfP2…
RT @LeonardAngka: Double feature of #naturalkiller cells and #COVID19 both officially out today! @jclinicalinvest https://t.co/ZNFRQfP2…
Double feature of #naturalkiller cells and #COVID19 both officially out today! @jclinicalinvest https://t.co/ZNFRQfP2zL @FrontiersIn #Immunology: https://t.co/dhB7KOOuom BONUS, check out our newly registered Phase III #clinicaltrial, COV-IMMUNO: htt
Proud of my lab for publishing this excellent COVID-19 review paper focusing on NK cell therapies @auer_r @mikennedyPhD https://t.co/vBdRdAbItb